Natco Pharma Ltd (NSE: NATCOPHARM) and Wockhardt Ltd (NSE: WOCKPHARMA) are both listed in the Medicinal Chemicals and Botanical Products industry. Natco Pharma has a market capitalisation of ₹15,414 Cr and Wockhardt ₹30,817 Cr, as of 9 Nov 2026. Their P/E ratios are 9.9 and 144.8 respectively. Return on equity is 16.85% for Natco Pharma and 4.00% for Wockhardt. Over one year, Natco Pharma's share price is down 3.2% and Wockhardt's is up 43.7%.
| Metric | Natco Pharma | Wockhardt |
|---|---|---|
| NSE Symbol | NATCOPHARM | WOCKPHARMA |
| BSE Code | 524816 | 532300 |
| Share Price | ₹805.00 | ₹2,031.50 |
| Market Cap | ₹15,414 Cr | ₹30,817 Cr |
| P/E Ratio | 9.9 | 144.8 |
| Return on Equity | 16.85% | 4.00% |
| Return on Assets | 7.98% | 3.67% |
| Dividend Yield | 0.57% | 0.00% |
| Beta (1Y) | 0.23 | 1.03 |
| 1-Year Price Change | -3.2% | +43.7% |
| 3-Month Price Change | -11.6% | +5.2% |
| 52-Week Range | ₹773.60 – ₹1,226.80 | ₹1,086.70 – ₹2,422.30 |
| Latest Quarter | Q1 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹735 Cr | ₹969 Cr |
| Quarterly Net Profit | ₹207 Cr | ₹73 Cr |
| Net Margin | 28.1% | 7.5% |
| EPS (Basic, Quarter) | ₹11.53 | ₹4.85 |
| Results Basis | consolidated | consolidated |
| Headquarters | Hyderabad, Telangana | Mumbai, Maharashtra |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and in…
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafith…
Wockhardt has a market capitalisation of ₹30,817 Cr, against ₹15,414 Cr for Natco Pharma as of 9 Nov 2026, about 2.0 times the size by market cap.
Natco Pharma has a P/E of 9.9 and Wockhardt a P/E of 144.8 as of 9 Nov 2026.
Natco Pharma has a return on equity of 16.85% and Wockhardt 4.00%.
Natco Pharma's share price is down 3.2% over one year and Wockhardt's is up 43.7%.
Natco Pharma reported revenue of ₹735 Cr and net profit of ₹207 Cr for Q1 FY27. Wockhardt reported revenue of ₹969 Cr and net profit of ₹73 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.